Dr. William D. Tap, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 108
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 260812 · CA license A83021 -
Internal Medicine Physician
CA license A83021
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 108
- Services billed
- 312
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 147 | 57 |
| Established patient office or other outpatient visit, 30-39 minutes | 143 | 67 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 73 |
| Gleevec (imatinib mesylate) | 20 |
| Verzenio (abemaciclib) | 14 |
| Dexamethasone Other prescribers in New York, NY | 14 |
| Amlodipine Besylate Other prescribers in New York, NY | 13 |
| Cabometyx (cabozantinib s-malate) | 13 |
| Votrient (pazopanib hcl) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 31 payments worth $38,425 in total to this clinician.
| Daiichi Sankyo Inc. | $10,846 |
|---|---|
| EMD Serono Research & Development Institute, Inc. | $6,373 |
| Recordati_rare_diseases_inc. | $6,344 |
| Ipsen Bioscience Inc. | $5,460 |
| EMD Serono, Inc. | $5,212 |
| GlaxoSmithKline, LLC. | $1,900 |
| Deciphera Pharmaceuticals Inc. | $1,699 |
| Merck Kgaa | $525 |
| Consulting Fee | $34,786 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,488 |
| Food and Beverage | $1,244 |
| Travel and Lodging | $696 |
| Gift | $212 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. May 14, 2025 | Consulting Fee Turalio · ONCOLOGY | $9,675 |
| Recordati_rare_diseases_inc. Jan 25, 2025 | Consulting Fee | $5,880 |
| Ipsen Bioscience Inc. Jul 2, 2025 | Consulting Fee | $5,460 |
| EMD Serono, Inc. Oct 6, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $4,973 |
| EMD Serono Research & Development Institute, Inc. Apr 9, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $4,273 |
| EMD Serono Research & Development Institute, Inc. Jun 11, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $2,100 |
| GlaxoSmithKline, LLC. Dec 23, 2025 | Consulting Fee | $1,900 |
| Deciphera Pharmaceuticals Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $1,488 |
| Merck Kgaa Sep 2, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $525 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $372 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 23, 2025 | Consulting Fee | $1,900 |
| Deciphera Pharmaceuticals Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $1,488 |
| Deciphera Pharmaceuticals Inc. Nov 12, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $87.29 |
| Deciphera Pharmaceuticals Inc. Nov 12, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $63.36 |
| Deciphera Pharmaceuticals Inc. Nov 12, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $61.14 |
| EMD Serono, Inc. Oct 6, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $4,973 |
| Merck Kgaa Sep 2, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $525 |
| Ipsen Bioscience Inc. Jul 2, 2025 | Consulting Fee | $5,460 |
| EMD Serono Research & Development Institute, Inc. Jun 11, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $2,100 |
| Daiichi Sankyo Inc. May 14, 2025 | Consulting Fee Turalio · ONCOLOGY | $9,675 |
| EMD Serono Research & Development Institute, Inc. Apr 9, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $4,273 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $372 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $249 |
| Daiichi Sankyo Inc. Mar 28, 2025 | Travel and Lodging Turalio · ONCOLOGY · travel to MIAMI, FL · in-kind | $75.38 |
| Recordati_rare_diseases_inc. Jan 25, 2025 | Consulting Fee | $5,880 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $221,467 in research payments for these studies, mostly to the institutions running them.
- Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated …
Servier Bioinnovation - Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals Inc. · Active, not recruiting · NCT03069469
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.